Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

NCT00894387 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1639

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Decompensated Heart Failure
Congestive Heart Failure

Interventions

DRUG: Aliskiren
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals